We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Forum |
Creator pc4900074200 | Created 16 Nov 2006 | Posts 1039 | Last Post 6 years ago |
Free Annual Reports | Add Favourite|E-mail Alert|Related Threads |
AGM. 4th October 2007.
If name change goes ahead?
New thread VivoMedica Plc. Will be posted a.s.a.p.
Company Web Site.Zi Medical Plc.
AIM rule 26 link.www.oxfordnewtech.co.uk
Scroll down to view please.Medical Devices & Products.Link to ALL Product Presentations.InFusion Disposables.Zi Medical intravenous infusion disposable systems are designed to safely meet all types of acute care infusion needs. Regardless of your specific need - a complete drug delivery system or any number of individual components – Zi Medical delivers infusion technology to simplify your critical care procedures.ZI-167E4 - 2 WAY INFUSION SET WITH MICRODRIP LATEX FREEDetails.ZI-168E2 - 2 WAY INFUSION SET LATEX FREEDetails.ZI-168E2F - 2 WAY INFUSION SET FOR PHOTOSENSITIVE MEDICATIONS LATEX FREEDetails.ZI-168E2H - 2 WAY PVC FREE INFUSION SET LATEX FREEDetails.ZI-168E4 - 2 WAY INFUSION SET WITH MICRODRIP LATEX FREEDetails.ZI-169E2 - 2 WAY INFUSION SET LATEX FREEDetails.ZI-171E4F - 2 WAY INFUSION SET FOR PHOTOSENSITIVE MEDICATIONS LATEX FREEDetails.ZI-179E6 - 2 WAY INFUSION SET WITH FLOW REGULATOR LATEX FREEDetails.ZI-180E6 - 2 WAY INFUSION SET WITH FLOW REGULATOR LATEX FREEDetails.ZI-186E2F - 2 WAY INFUSION SET LATEX FREEDetails.ZI-193E2 - 2 WAY INFUSION SET LATEX FREEDetails.ZI-193E2F - 2 WAY INFUSION SET FOR PHOTOSENSITIVE MEDICATIONS LATEX FREEDetails.ZI-193E2H - 2 WAY PVC FREE INFUSION SET LATEX FREE Details.ZI-213E2 - 2 WAY INFUSION SET WITH NEEDLE LATEX FREEDetails.Z2-221E1 - 2 WAY BLOOD SET LATEX FREEDetails.Z2-252E1 - 2 WAY BLOOD SET LATEX FREEDetails.Z2-257E1 - 2 WAY BLOOD SET LATEX FREEDetails.Z3-413E4 - BLOOD BURETTE LATEX FREEDetails.Z3-423E4 - INFUSION BURETTE LATEX FREEDetails.Z4-602E1 - EXTENTION LINEDetails.Z4-602E5 - EXTENTION LINE WITH FLOW REGULATOR LATEX FREEDetails.Z4-07515 - EXTENTION LINE MICROBOREDetails.Z4-07529 - EXTENTION LINE STANDARDDetails.Z4-10015 - EXTENTION LINE MICROBOREDetails.Z4-10029 - EXTENTION LINE WIDE BOREDetails.Z4-15015 - EXTENTION LINE MICROBOREDetails.Z4-15029 - EXTENTION LINE STANDARDDetails.Z5-211E2 - 2 WAY INFUSION SET WITH IN LINE FILTER LATEX FREE - PVC FREEDetails.Z5-224E2P - 2 WAY INFUSION SET WITH IN LINE FILTER LATEX FREE – PVC FREEDetails.Z5-224E2P - 2 WAY INFUSION SET WITH IN LINE LATEX FREE – PVC FREEDetails.Z6-015E - SPIN OVER MALE LUER LOCK IN BLISTER PACKING – LATEX FREE – PVC FREEDetails.Z6-025E - 3 WAY STOP COCK PVC FREEDetails.Z6-054E - 3 WAY MANIFOLD PVC FREEDetails.Z7-504E - UROLOGICAL INFUSION SETDetails.Z7-505E - UROLOGICAL INFUSION SET Details.Z8-001E1 - 2 WAY INFUSION SET FOR ENTERAL FEEDING LATEX FREEDetails.Z8-402E1 - THORACENTESIS / PARACENTESIS SETDetails.Z8-012E1 - 2000 ML BAG FOR ENTERAL FEEDING WITH INFUSION SET LATEX FREEDetails.Z8-038E1 - 3000 ML BAG FOR PARENTERAL FEEDING LATEX FREEDetails.Z8-400E1 - THORACENTESIS / PARACENTESIS SETDetails.Z8-403E1 - THORACENTESIS / PARACENTESIS SET Details.Pathscore™Breast cancer is one of the most common cancers in women world-wide with numbers expected to increase as the population ages. A focus of healthcare systems is rapid and accurate diagnosis, which drives optimal treatment planning. The world-wide market for such diagnoses is already huge and will grow.A central element of diagnosis is the histopathological assessment of tissue biopsies. This subjective assessment is open to modernisation and automation to improve reliability, screening throughput and exchange of data. Pathscore is a PC software-based approach that delivers these improvements. It has been developed by QinetiQ in conjunction with academic and healthcare experts, and validated against existing data.Pathscore operates on a number of synergistic levels to enhance and standardise pathologists’ diagnoses:Image digitisation and compression.Microscope images of histopathological slides of tissue biopsies are captured into digital files. To facilitate, use and transmit these very large data files, patented novel QinetiQ image-compression techniques are used to reduce file size without loss of diagnostic information. Images can be edited to highlight and annotate key features as an aid to improve diagnosis traceability, without loss of original raw data.Automatic histopathological data analysis.Using automatic software detection and grading of diagnostic parameter (including cerbB2 status, facilitating targeted treatment with herceptin) digital images are rapidly and reproducibly assessed for management review.Telepathology.Original digital images, together with highlights and annotations, can be transmitted over standard telecommunication networks for discussion, case-conferences, review, research or storage as requiredHistopathological database.This is an interactive web-based database which could be hospital, area, country or even internationally focused in operation. The database enables remote storage, searching, indexing and retrieval, together with automatic analysis of histopathology slides.Building on the validated utility of Pathscore in breast cancer will involve extrapolation to other solid tumour diagnosis, starting with prostate cancer. Again this market is large and there is a need to modernise and automate. Zi Medical’s collaboration with academic and healthcare groups will initially identify diagnostic indicators, both presently and in the near future, before Pathscore is reoriented towards automatic detection and grading of those indicators.Pathscore™DrugPrint™The components of this technology, also originally developed at QinetiQ will form an exhaustive pre-clinical testing system for potential pharmaceutical compounds.The components of this technology, also originally developed at QinetiQ will form an exhaustive pre-clinical testing system for potential pharmaceutical compounds.It is designed to help identify structure-activity relationships in drugs and should significantly reduce the number of compounds that fail in toxicology and in early stage clinical development.The system is based on the use of micro-electrode array plate technology and enables long term, non-invasive recordings to be made of the electrical activity generated in cells forming a functional syncitium when cultured on the plate.The technology offers a unique insight into the integrated behaviour of cells within an in vitro network, providing a robust platform for high throughput drug screening.The key features are as follows:· Rapid characterisation and screening of drug compounds· More efficient and effective experimentation· Use of live cells and with reduced animal dependence.· Cost reduction in toxicology testing· Long term, non-invasive monitoringThe system provides a finger print read-out characterising 41 features giving a reliable, consistent and biologically relevant series of results.Although the system will be used initially in cardiovascular drug design and testing the technology is applicable to all organ types. As such it is an example of technology with much wider applications (often referred to as “platform technology”)..DrugPrint™Research & Developmentdevice development servicesOur research and development services are focused on next generation medical products, technologies, intellectual property and emerging markets. We see these areas as crucial to development within healthcare.We have broad ranging expertise in the fields of:Electronics Design - Hardware/Software development, safety critical software and high reliability design and development, including full support documentation.Product Design - Industrial Design and Mechanical Engineering, applying an empathic design process with rigorous engineering practices.Regulatory Approvals - Structured to customer requirements including TUV, FDA, BSI etc.Our success is achieved through a fully integrated approach to medical device development underpinned by a highly creative yet grounded team. We create fresh ideas with an understanding of real market needs.We have a proven record of working with major healthcare companies, creating next generation products from complex capital devices to disposable goods with the implementation of protected new technologies and ideas.“An innovative medical devices business, operating in the global market place, specialising in the rapid development of new concept devices that provide a helping hand for today’s ward staff”.Zimed Ltd. was founded in April 1999 to exploit the opportunities presented by a range of medical devices being developed by George Gallagher.The company's first product, Red-Eye™ is a globally patented method and apparatus for monitoring intravenous drips. In the year 2000, in record time, the device gained regulatory approval. In 2001 George Gallagher presented the Red-Eye™ monitor on the BBC's Tomorrow's World programme and won the Inventor of the Year Award for Health Innovation. In 2003 a worldwide distribution agreement for this product was signed with one of the largest international healthcare companies, Baxter Healthcare Corporation.Zi Medical continues to extend its range of products following the same theme of safe fluid delivery. A family of syringe drivers has been developed which utilises a new, patented method of back pressure detection. Also, a range of fluid delivery consumables specialising in needle-free systems has been added to the portfolio. It is the company's intention to seek further partnering arrangements to exploit these products on a commercial basis.Contact & Locationwe would like to hear from youGeneral Enquiries: admin@zi-medical.comBy postZi Medical plcClinical Devices & DiagnosticsBuilding 110/130Abbott DriveKent Science ParkSittingbourneKent ME9 8AZTel: 01795 414468Fax: 01795 414461Used from Zi Medical Plc web-site. 16-11-2006. & zimed.co.uk. 07-10-07 pc
No news found
Stock Charts
|